Showing results (31-40 of 1,607) with videos related to
Sort By:
Pageof 161
Investigational New Drugs|January 7, 2004
Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patientsC Kloft, E-U Graefe, P Tanswell, et al.Diabetes, Obesity & Metabolism|June 16, 2011
Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*)U Graefe-Mody, C Friedrich, A Port, et al.Artificial Organs|February 1, 1978
Uremic neuropathy: evidence of middle molecule toxicityJ Milutinovic, A L Babb, J W Eschbach, et al.The American Journal of Cardiology|November 21, 2000
Past and future technologic developments for rhythm and conduction disturbancesJ WarrenAdvances in Experimental Medicine and Biology|January 1, 1976
Lymphocyte surface-attached immunoglobulins in some clinical conditionsJ WarrenDiabetes, Obesity & Metabolism|January 23, 2016
Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeksS Freude, T Heise, H-J Woerle, et al.Diabetic Medicine : a Journal of the British Diabetic Association|November 10, 2010
Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetesT Forst, B Uhlig-Laske, A Ring, et al.Current Genetics|November 1, 2013
Mitotic segregation of 2 μm-pbr322 chimaeric plasmids in yeastG J WarrenOecologia|November 19, 2025
Environmental resistance mediates propagule pressure in a novel plant communityRobert J WarrenPageof 161